MPL and acute myeloid leukemia: No difference in mortality, serious adverse events, platelet transfusion, hematologic improvement, and AML transformation was observed.<h4>Conclusions</h4>Thrombopoietin receptor agonists (TPO-RAs) romiplostim and eltrombopag were effective in reducing bleeding events, especially grade ≥3 bleeding events.